Overview
From a portfolio lens, TUSD ($492.35M) and Injective ($490.41M) offer different beta to bitcoin cycles. The overview below keeps the facts first and the narrative second.
Quick winners
Full comparison
| Metric | TUSD | INJ |
|---|---|---|
| Price | $0.996400 | $5.08 |
| Market Cap | $492.35M | $490.41M |
| FDV | — | — |
| Volume 24h | $24,801.94 | $2.27M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 100.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.64% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | TUSD | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +0.03% | +4.65% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | TUSD | INJ |
|---|---|---|
| RSI | 49.02 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 67.35 | 0.29 |
| ADX | 21.33 | 12.19 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.47 |
| Trend | bearish | neutral |
| Momentum | 63.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, TUSD shows RSI 49.02 with trend bias bearish, while Injective sits at RSI 49.29 (neutral). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | TUSD | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
TUSD
Injective
Pros and cons
Pros of TUSD
- Composite PEPS readings for TUSD can surface clearer module agreement during trend phases.
- Market-cap scale on TUSD may dampen some idiosyncratic shocks versus smaller peers.
- TUSD has an established coin page footprint on PEPS for continuous monitoring.
Cons of TUSD
- When dominance narratives fade, TUSD can lag hotter rotation names.
- Large-cap status for TUSD can mean slower percentage upside versus high-beta alternatives.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
Pros of Injective
- Active volume bursts on INJ sometimes precede sharper tactical moves.
- Diversifying versus TUSD with Injective can change portfolio factor exposure.
- Injective can offer higher relative beta when market attention rotates toward its niche.
- Narrative optionality around Injective can reprice quickly when catalysts appear.
Cons of Injective
- Trend failures on Injective often travel faster than on more established assets.
- Smaller book depth versus large caps can increase slippage for Injective.
- Relative underperformance versus TUSD can persist through entire market regimes.
- Weaker market-cap standing may leave Injective more exposed to liquidity droughts.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to TUSD, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
For readers asking which is “better”, the honest answer is conditional. TUSD and Injective solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, TUSD or Injective?
“Better” depends on horizon and risk. TUSD leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, TUSD or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both TUSD and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.